Antifungal Combination Therapy for Invasive Aspergillosis
| Autor: | Ildefonso Espigado, Manuela Aguilar-Guisado, Almudena Martín-Peña, José Miguel Cisneros |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Microbiology (medical)
Antifungal medicine.medical_specialty Antifungal Agents Combination therapy medicine.drug_class Cost-Benefit Analysis Drug Evaluation Preclinical Salvage therapy Context (language use) Aspergillosis law.invention Randomized controlled trial law Animals Humans Medicine Combined Modality Therapy Intensive care medicine Clinical Trials as Topic Cost–benefit analysis business.industry medicine.disease Treatment Outcome Infectious Diseases Drug Therapy Combination business |
| Zdroj: | Clinical Infectious Diseases. 59:1437-1445 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/ciu581 |
| Popis: | The outcome of invasive aspergillosis (IA) continues to be associated with significant attributable mortality, especially in patients with hematological malignancies and in hematopoietic stem cell transplant recipients. In this context, antifungal combined therapy (ACT) has become an emerging strategy against IA. In an attempt to evaluate the benefits of ACT, a large number of experimental studies, clinical series, and randomized trials have been performed, with varying results. In addition, several controlled trials have been registered; however, in most cases, their final results have not been made available. In summary, there is an imbalance between the lack of published evidence regarding the benefits of ACT and its extensive and increasing use in current clinical practice, despite its associated cost. Here, we present a critical analysis of the available information regarding ACT for the treatment of IA as well as the authors' opinion with respect to its use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|